DK1930439T3 - Neurotrofe faktorer - Google Patents

Neurotrofe faktorer

Info

Publication number
DK1930439T3
DK1930439T3 DK07120461.4T DK07120461T DK1930439T3 DK 1930439 T3 DK1930439 T3 DK 1930439T3 DK 07120461 T DK07120461 T DK 07120461T DK 1930439 T3 DK1930439 T3 DK 1930439T3
Authority
DK
Denmark
Prior art keywords
neurotrophic factors
neublastin
polypeptides
methods
antibodies
Prior art date
Application number
DK07120461.4T
Other languages
English (en)
Inventor
Dinah Wen Yee Dr Sah
Teit E Dr Johansen
Anthony Dr Rossomando
Original Assignee
Biogen Idec Inc
Nsgene As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Nsgene As filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of DK1930439T3 publication Critical patent/DK1930439T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
DK07120461.4T 2001-03-12 2002-03-12 Neurotrofe faktorer DK1930439T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/804,615 US20020055467A1 (en) 1998-07-06 2001-03-12 Novel neurotrophic factors
EP02706759A EP1373503B1 (en) 2001-03-12 2002-03-12 Neurotrophic factors

Publications (1)

Publication Number Publication Date
DK1930439T3 true DK1930439T3 (da) 2011-08-29

Family

ID=25189406

Family Applications (2)

Application Number Title Priority Date Filing Date
DK02706759T DK1373503T3 (da) 2001-03-12 2002-03-12 Neurotrofiske faktorer
DK07120461.4T DK1930439T3 (da) 2001-03-12 2002-03-12 Neurotrofe faktorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK02706759T DK1373503T3 (da) 2001-03-12 2002-03-12 Neurotrofiske faktorer

Country Status (16)

Country Link
US (1) US20020055467A1 (da)
EP (2) EP1930439B1 (da)
JP (2) JP3738008B2 (da)
CN (1) CN1268744C (da)
AT (2) ATE509103T1 (da)
AU (1) AU2002240943B2 (da)
CA (1) CA2440767C (da)
CY (1) CY1111750T1 (da)
DE (1) DE60223511T2 (da)
DK (2) DK1373503T3 (da)
ES (2) ES2296899T3 (da)
HK (1) HK1120556A1 (da)
NZ (1) NZ528790A (da)
PT (2) PT1373503E (da)
SI (2) SI1373503T1 (da)
WO (1) WO2002072826A2 (da)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
PL209952B1 (pl) * 1998-07-14 2011-11-30 Janssen Pharmaceutica Nv Wyizolowana cząsteczka kwasu nukleinowego, wyizolowany ludzki neurotroficzny czynnik wzrostu, plazmid, wektor ekspresyjny, komórka gospodarza, zastosowania cząsteczki kwasu nukleinowego, zastosowania neurotroficznego czynnika wzrostu, kompozycje faramaceutyczne, przeciwciało oraz sposób wykrywania neurotroficznego czynnika wzrostu
NZ526610A (en) * 2000-12-22 2009-08-28 Genentech Inc New use of artemin, a member of the GDNF ligand family
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
AU2002250203B2 (en) * 2001-03-28 2006-08-10 Biogen Ma Inc. Use of neublastin polypeptides for treating neuropathic pain
JP2005516949A (ja) * 2001-12-19 2005-06-09 リジュン・ワン Ｇｄｎｆの骨格筋へのアデノ随伴ウイルス媒介性のデリバリー
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
ES2351215T3 (es) * 2003-01-31 2011-02-01 Biogen Idec Ma Inc. Conjugados poliméricos de neublastina mutada.
CA2522364C (en) * 2003-04-18 2014-12-09 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
WO2004108760A2 (en) * 2003-06-10 2004-12-16 Nsgene A/S Improved secretion of neublastin
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
NZ547185A (en) 2003-10-20 2009-03-31 Nsgene As In vivo gene therapy of parkinson's disease
SI1786454T1 (sl) * 2004-08-19 2010-10-29 Biogen Idec Inc Variante neoblastina
CA2577690C (en) 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
EP1937295A2 (en) * 2005-10-11 2008-07-02 NS Gene A/S Treatment of retinopathies using gfr 3 agonists
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
US20100056440A1 (en) * 2006-03-01 2010-03-04 Biogen Idec Ma Inc. Compositions and methods for administering gdnf ligand family proteins
CA2685686A1 (en) * 2007-05-01 2008-11-13 Biogen Idec Ma Inc. Neublastin polypeptides for use increasing vascularization in a tissue
WO2009020964A2 (en) * 2007-08-08 2009-02-12 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
WO2009045813A1 (en) * 2007-10-01 2009-04-09 Vgx Pharmaceuticals, Inc. Materials and methods for the delivery of biomolecules to cells of an organ
AU2011307488B2 (en) * 2010-10-01 2015-08-20 Hoba Therapeutics Aps Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
US20190381138A1 (en) * 2018-05-17 2019-12-19 Helixmith Co., Ltd. Treatment of neuropathic pain associated with chemotherapy-induced peripheral neuropathy
EP4353251A1 (en) 2021-05-18 2024-04-17 LTT Bio-Pharma Co., Ltd. Pharmaceutical composition for treating or preventing disorder associated with administration of anticancer agent

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
EE9800377A (et) 1996-05-08 1999-04-15 Biogen, Incorporated Ret-i ligand (RetL) närvi- ja neerukasvu stimuleerimiseks
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US6284540B1 (en) * 1998-09-29 2001-09-04 Washington University Artemin, a novel neurotrophic factor
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
EP1185648B1 (en) * 1999-06-02 2007-03-21 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth

Also Published As

Publication number Publication date
JP2005198656A (ja) 2005-07-28
CY1111750T1 (el) 2015-10-07
JP3738008B2 (ja) 2006-01-25
JP2004531242A (ja) 2004-10-14
DE60223511D1 (de) 2007-12-27
DK1373503T3 (da) 2008-03-25
ES2296899T3 (es) 2008-05-01
CN1509333A (zh) 2004-06-30
EP1930439B1 (en) 2011-05-11
DE60223511T2 (de) 2008-10-23
CN1268744C (zh) 2006-08-09
EP1373503A2 (en) 2004-01-02
EP1930439A1 (en) 2008-06-11
PT1930439E (pt) 2011-07-25
ES2366610T3 (es) 2011-10-21
US20020055467A1 (en) 2002-05-09
WO2002072826A3 (en) 2003-04-10
HK1120556A1 (en) 2009-04-03
CA2440767A1 (en) 2002-09-19
WO2002072826A2 (en) 2002-09-19
CA2440767C (en) 2012-05-29
AU2002240943A2 (en) 2002-09-24
ATE509103T1 (de) 2011-05-15
ATE378353T1 (de) 2007-11-15
PT1373503E (pt) 2008-02-26
AU2002240943B2 (en) 2007-05-10
SI1373503T1 (sl) 2008-04-30
NZ528790A (en) 2004-06-25
SI1930439T1 (sl) 2011-09-30
EP1373503B1 (en) 2007-11-14

Similar Documents

Publication Publication Date Title
CY1111750T1 (el) Νευροτροφικοι παραγοντες
ATE522609T1 (de) Neurotrophe faktoren
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
PT1015585E (pt) Homologos de ligandos de tie
PL374178A1 (en) Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
BR0012759A (pt) Neurotoxinas recombinantes ativáveis
NO20054836L (no) Nogo-reseptorbindingsprotein
WO2007045019A3 (en) Polyoleosins
ATE309356T1 (de) Konstruierte fluoreszenzproteine mit langen wellenlängen
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
EA200100110A1 (ru) Нейротрофические факторы
ATE325873T1 (de) Androgenrezeptor-komplex assoziiertes protein
WO2001021794A3 (en) Smad associating polypeptides